| DB ID | MyCo_2463 |
| Title | Invasive aspergillosis in patients with underlying liver cirrhosis: a prospective cohort study |
| Year | 2017 |
| PMID | 28431001 |
| Fungal Diseases involved | Invasive aspergillosis |
| Disease | Aspergillosis (Aspergillus Infection) |
| Associated Medical Condition | liver cirrhosis |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | Unspecified |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Austria |
| Cohort | 50 patients were included in the study. |
| Cohort No. | 150 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.5 |
| Specificity | 0.97 |
| Positive Predictive Value | 0.17 |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is a disease primarily affecting im-munocompromised patients. Several factors, for example, prolonged neutropenia as well as glucocorticoid use in case of graft-versus-host disease predispose patients for IA. Re- cently, IA has also increasingly been reported in critically ill patients without hematological malignancies and solid organ transplant recipients. |
| Sub Technique | ELISA |
| Technique | Immunoassay |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad, Vienna, Austria) |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
